Ebola viruses (EBOVs) are responsible for repeated outbreaks of fatal infections, including the recent deadly epidemic in West Africa. There are currently no approved therapeutic drugs or vaccines for the disease. EBOV has a membrane envelope decorated by trimers of a glycoprotein (GP, cleaved by furin to form GP1 and GP2 subunits), which is solely responsible for host cell attachment, endosomal entry and membrane fusion 1-7 . GP is thus a primary target for the development of antiviral drugs. Here we report the first, to our knowledge, unliganded structure of EBOV GP, and high-resolution complexes of GP with the anticancer drug toremifene and the painkiller ibuprofen. The high-resolution apo structure gives a more complete and accurate picture of the molecule, and allows conformational changes introduced by antibody and receptor binding to be deciphered 8-10 . Unexpectedly, both toremifene and ibuprofen bind in a cavity between the attachment (GP1) and fusion (GP2) subunits at the entrance to a large tunnel that links with equivalent tunnels from the other monomers of the trimer at the three-fold axis. Protein-drug interactions with both GP1 and GP2 are predominately hydrophobic. Residues lining the binding site are highly conserved among filoviruses except Marburg virus (MARV), suggesting that MARV may not bind these drugs. Thermal shift assays show up to a 14 °C decrease in the protein melting temperature after toremifene binding, while ibuprofen has only a marginal effect and is a less potent inhibitor. These results suggest that inhibitor binding destabilizes GP and triggers premature release of GP2, thereby preventing fusion between the viral and endosome membranes. Thus, these complex structures reveal the mechanism of inhibition and may guide the development of more powerful anti-EBOV drugs.
LETTER RESEARCH Data Fig. 1) . In a mouse model 14 , toremifene appears to be even more potent (half-maximum inhibitory concentration (IC 50 ) ~1 μM).
The crystal structure of unliganded EBOV GP was determined at 2.2 Å resolution, with good R-factors and stereochemistry (Extended Data Table 1 ). Three copies each of the GP1 and GP2 subunits ( Fig. 2a ) form the biological trimer around the crystallographic three-fold axis (Fig. 2b, c ). This structure, although crystallized at pH 5.2, represents the pre-fusion state of the molecule, with the GP1 receptor-binding site blocked by a glycan cap ( Fig. 2e ). GP1 is predominantly composed of β-strands, forming a large semi-circular groove at the centre of the subunit that clamps the α3 helix and β19-β20 strands of GP2 (Fig. 2d ). The glycan cap is removed in the late endosome by cathepsin B/L to expose the receptor Niemann-Pick disease type C1 (NPC1)-binding site 9, 20, 21 . GP2 catalyses membrane fusion and contains N-terminal (α3 and α4) and C-terminal (α5) heptad repeats linked by a CX 6 CC motif (residues 601-609, Fig. 2a ). The C-terminal heptad repeat, disordered in all previously published GP structures [8] [9] [10] , contributes to the trimer interface in our structure ( Fig. 2b , c) and contains N618, which is glycosylated as predicted. The well-ordered CX 6 CC motif forms intrasubunit (C601-C608), and intersubunit (C53-C609) disulfide bonds ( Fig. 3 ). Mutation of any of these cysteine residues renders the virus incapable of entering host cells 22 . In the fusion process, GP2 undergoes conformational changes in which α5 refolds onto a helix coalesced from α3 and α4 to form a six-helix bundle 23 (Extended Data Fig. 2 ). In our prefusion structure, the hydrophobic GP2 fusion loop (residues 511-554) ( Fig. 2a ) projects into a neighbouring monomer and is stabilized in a shallow depression surrounded by loops β4-β5 and β10-β11, and α3. Apart from residues 521-526, which have very loose interactions with the rest of the protein, the fusion loop in this pH 5.2 apo GP is very similar to that in the KZ52 Fab complex crystallized at pH 8.3 (Extended Data Fig. 3 ). This is in contrast to the large conformational changes reported for the isolated fusion loop at different pHs (ref. 24 ), suggesting that GP1 maintains GP2 in the pre-fusion state until their separation triggered by receptor binding.
In total, 319 out of 394 Cα atoms in our apo GP structure match with the GP-Fab complex 8 , with a root mean squared deviation (r.m.s.d.) value of 1.1 Å ( Fig. 3a-d) , however, there are marked differences, beyond the C-terminal heptad repeat and CX 6 CC motif. The β1-β2 hairpin interacts directly with the KZ52 Fab and is pushed 6 Å inwards in the Fab complex ( Fig. 3c ). The glycan cap is better ordered in the apo structure, revealing an extra strand, β18′, inserted between β17 and β18, overlapping β18 in the Fab complex but running in the opposite direction ( Fig. 3b) . Several cross-reactive neutralizing monoclonal antibodies from EBOV survivors bind to the cap 25 , suggesting that this conserved epitope is important for antibody-mediated clearance of the virus. Our structure defines this conformational epitope.
In the apo GP structure (excluding the glycan cap), 230 Cα atoms overlay with the GP in the NPC1 receptor complex 9 , with an r.m.s.d. of 0.9 Å (Fig. 3e ). NPC1 binding draws helix α1 approximately 2 Å towards the receptor, causing the preceding 3 10 -helix α1′ to unwind, disrupting interactions with α3 of GP2, as described previously 9 (Fig. 3f ). These structural changes also break hydrogen bonds from α1′ to the amide groups of residues K510 and N512, disordering the N-terminal residues 502-507 of GP2. The structural differences continue to the other side of α3. In the NPC1-bound structure, the α3 helix starts two residues earlier and the β1-β2 hairpin bends inwards, adopting a conformation similar to that in the KZ52 Fab complex ( Fig. 3c, g ). In addition, there is a large tunnel between neighbouring monomers ( Fig. 4 , Extended Data Fig. 4 ), whose hydrophobic entrance is formed by surrounding residues from the β1-β2 hairpin, β3, β6 and β13 of GP1, and α3, β19 and β20 of GP2. Residues 192-195 (with sequence DFFS, and named DFF lid thereafter) form a tight turn with F193 and F194 plugging the entrance of the tunnel and making tight 
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interactions with β19 and β20 ( Fig. 4a and Extended Data Fig. 5a ). This structure may also hold the putative cleavage site residue 190 in position (Extended Data Fig. 5a )-in the endosome the glycan cap is cleaved to free the receptor-binding site of GP1 (refs [25] [26] [27] [28] [29] , which also exposes the entrance of the tunnel. Receptor binding is proposed to trigger unwinding of GP2 from GP1 and subsequently lead to membrane fusion 23 . The above structural changes resulting from receptor binding probably all contribute to weaken GP1-GP2 interactions. Both α1′ and α1 are shielded by residues 287-293 and the N563 glycan (which is resistant to enzymatic deglycosylation), perhaps preventing premature release of GP2 (Extended Data Fig. 6 ).
Structures of GP-toremifene and GP-ibuprofen complexes were obtained by crystal soaking and refined to 2.7 Å resolution (Extended Data Table 1 ). Both inhibitors have well-defined electron density and bind at the same site at the entrance of the large tunnel by expelling the DFF lid ( Fig. 4 and Extended Data Figs 4, 5, 7) . In addition to the tunnel entrance residues already mentioned, the tunnel is lined by residues from the N-terminal loop, the β1-β2 hairpin, β2-β3 loop of GP1, and α3 and α4 of GP2 from a neighbouring monomer, and interconnected with the other two tunnels in the trimer at the three-fold axis ( Fig. 4b and Extended Data Fig. 4 ). Y517 makes dominant interactions with toremifene by contacting all three phenyl rings (Fig. 4c ). In addition, phenyl ring A of toremifene is fully buried and interacts with V66, L68, L515 and L558, ring B with L186, and ring C with V66 and A101. The ethyl chloride group interacts with L184, L186, M548 and L558, while the dimethylethanamine group points towards the main tunnel and is surrounded by polar/charged residues, including R64, E100, T519, T520 and D522 (Fig. 4c ).
Ibuprofen is bound with its isobutyl group partially overlapping the ethyl chloride group of the toremifene but closer to L554. However, its phenyl ring does not overlap any of the rings of toremifene (Extended Data Fig. 5 ), but makes extensive interactions with M548 ( Fig. 4d ). The propanoic acid moiety is orientated to make a hydrogen bond to the side chain of R64 and hydrophobic interactions with Y517. Remarkably, ibuprofen was initially suggested to interact with EBOV GP by in silico screening, and predicted to dock in a pocket of the mucin domain 12 . A racemic mixture of ibuprofen was used for all experiments, however, we note that the S-isomer (which is also active as a painkiller) binds preferentially.
The flexible region, 521-526, of the fusion loop is stabilized in the two inhibitor-bound structures, but in different conformations compared to apo GP. The most notable conformation changes induced by toremifene are at side chains of M548 and L554, and M548 by ibuprofen ( Fig. 4 ). The residues involved in inhibitor binding are highly conserved across filoviruses, with the exception of MARV (Extended Data Fig. 8 ), where the DFF lid and its preceding loop are replaced by a helix, and V66 and A101 are substituted by M50 and E85, respectively, partially blocking the binding site 30 .
The SERMs tamoxifen, 4-hydroxytamoxifen and clomiphene are less potent inhibitors, despite their chemical similarity to toremifene 14, 15 . Compared to the ethyl chloride group of toremifene, the corresponding ethyl group in tamoxifen and chlorine in clomiphene are expected to make weaker interactions with L184, L186, M548 and L558. A partially bound 4-hydroxytamoxifen structure obtained by crystal soaking 
(data not shown) shows the hydroxyl group makes close contacts with G67, shifting the whole inhibitor ~1.0 Å towards the solvent, weakening ring-stacking interactions with Y517 and having no contacts from the ethyl group to L184, L186 and L558 compared to toremifene. Our crystallographic results are in line with the inhibition data [14] [15] [16] and our thermal-shift assay (Extended Data Fig. 1e, f) . If toremifene and ibuprofen inhibit viral infection by causing premature conversion of GP to the post-fusion conformation or blocking receptor binding, we would expect them to abolish viral fusion. This was confirmed by measuring their effect on the fusion of EBOV GP pseudoviruses as judged by a β-lactamase reporter assay (Extended Data Fig. 9 ). Benztropine, which decreases the T m of GP by 4 °C, could not be soaked in our crystals, and needs further investigation (Extended Data Fig. 1f ).
Our results pinpoint the binding site of toremifene and ibuprofen on the surface of the GP and reveal that they decrease the stability of the viral GP, and prevent viral fusion. The binding site is different to that predicted for ibuprofen 12 , and the information on the binding modes of these compounds and the spare volume at the binding cavity can guide the design of more potent compounds. Finally, our readily grown well-diffracting crystals are suitable for fragment-based screening for different classes of binders for the development of new inhibitors to combat EBOV infection.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.

METHODS
No statistical methods were used to predetermine sample size. The experiments were not randomized, and investigators were not blinded to allocation during experiments and outcome assessment. Protein cloning, expression and purification. Zaire EBOV (strain Mayinga-76) glycoprotein extracellular domain DNA was synthesized (UniProt entry KB-Q05320). The expression construct GPΔ contains two directly linked sections, amino acids 32-312 and 464-632, with a T42A mutation to eliminate N40 glycosylation. At the N terminus of the protein, the four amino acids ETGR were added from the expression vector pNeosec 31 . At the C terminus, a foldon trimerization sequence from the bacteriophage T4 fibritin and a 6× His tag were added with the sequence: GSGYIPEAPRDGQAYVRKDGEWVLLSTFLGTHHHHHH. The endotoxin free pNeosec-GPΔ plasmid was transiently transfected into the human embryonic kidney HEK293T (ATCC CRL11268) cells with polyethylenimine (PEI, molecular mass 25 kDa, Sigma). To inhibit the formation of complex glycosylation, the mannosidase inhibitor kifunensine (Cayman Chemical) was added to a final concentration of 5 μM. After 5 days of transfection, the conditioned media was collected, dialysed against PBS and incubated with talon beads (Takara Bio Europe SAS) at 15 °C for 1 h with gentle shaking. The beads were collected and washed with PBS plus 5-10 mM imidazole. The protein was eluted with 200 mM imidazole in PBS and further purified by size exclusion chromatography with a Superdex 200 HiLoad 16/600 column (GE Healthcare) and a buffer of 10 mM MES, pH 5.2, 150 mM NaCl. Thermal-shift assay. 10 μl of solution containing 2 μM glycosylated EBOV GP protein, buffered by the addition of 10 μl of 850 mM sodium malonate at the desired pH, was mixed with 10 μl of 15× SYPRO Orange dye (Thermo Fisher Scientific), along with 10 μl of 50 μM compound in 10% DMSO or just 10% DMSO. The mixture was made up to a total volume of 50 μl. Samples were placed in a semi skirted 96-well PCR plate (4 Titude), sealed and heated in an Mx3005p qPCR machine (Stratagene, Agilent Technologies) from 24.5 to 98.5 °C at a rate of 1 °C min −1 . Fluorescence changes were monitored with excitation and emission wavelengths at 492 and 610 nm, respectively. Reference wells, that is, solutions without chemical, but with the same amount of DMSO, were used to compare the melting temperature (T m ). Experiments were carried out in triplicate. Compounds tested included toremifene, tamoxifen, 4-hydroxyltamoxifen, anastrozole, benztropine, clomipramine, ibuprofen, diacylglycerol kinase inhibitor and benzodiazepine. The SERMs endoxifen and clomiphene could not be tested since they bind to SYPRO Orange directly. Ebola pseudovirus production and titration. HIV-1-derived pseudoviruses expressing the Ebola virus envelope glycoproteins (EBOV pseudoparticle, EBOVpp) were produced as described previously 32 . HEK-293T cells in T175 flasks were transfected with 2 μg pR8ΔEnv, 2 μg BlaM-Vpr, 1 μg pcREV and 3 μg of plexm-EBOV_GP plasmids (containing Zaire EBOV GP residues 1-676 under control of β-actin/CMV chimaeric promoter). After 8 h of transfection, the medium was replaced by fresh DMEM with 10% FBS. Viral supernatants were collected and concentrated using the Lenti-X Concentrator (Clontech). Virus titres were determined by infecting TZM-bl cells (PTA-5659, no mycoplasma contamination) with a serial dilution of concentrated pseudovirus followed by a β-Gal assay. Since the TZM-bl cells contain a β-Gal expression cassette with an HIV-1-induced promoter infected cells can be identified through hydrolysis of X-gal 33 . BlaM assay and analysis. The β-lactamase assay 33 was applied to assess EBOVpp fusion. 24 h before the assay TZM-bl cells were plated at 4 × 10 4 cells per well in black clear-bottomed 96-well plates. On the day of assay, cells were cooled on ice before the addition of EBOVpp (MOI 0.5), then centrifuged at 2,100g for 30 min at 4 °C. Viral supernatants were removed and cells washed with PBS. Then, 100 μl of DMEM plus 10% FBS containing toremifene (15 μM or 1.5 μM), ibuprofen (150 μM or 15 μM), or the same amount of solvent for the above compounds (5% DMSO) was added to each well before placing in a 37 °C, CO 2 incubator to initiate viral entry. After 120 min, cells were loaded with 1× CCF2-AM from the LiveBLAzer FRET-B/G Loading Kit (Life Technologies) and incubated at room temperature in the dark for 2 h. After CCF2-AM removal, cells were washed with PBS and fixed with 2% PFA before viewing. Cells were excited using a 405 nm continuous laser (Leica) and the emission spectra between 430 and 560 nm were recorded pixel by pixel (512 × 512) using a Leica SP8 X-SMD microscope with a 20× objective. The ratio of blue emission (440-480 nm, cleaved CCF2-AM) to green (500-540 nm, uncleaved CCF2-AM) was then calculated pixel by pixel using a customized macro 34 for ImageJ (http://imagej.nih.gov/ij/) with ten different observation fields for each condition. A blue/green threshold (fusion threshold) was set using HIV NoEnv virions containing Vpr-BlaM as a background control to provide a fusion detection limit that corresponded to 0.75 ± 0.05 BlaM ratio. The fusion threshold was calculated recovering the signal (blue/green intensity ratio) coming from individual cells plus 2× s.d. from ~200 cells in the observation field. This threshold was then applied to all conditions. Cells above the threshold were pseudocoloured in red and cells below the threshold pseudocoloured in blue. 'Red' cells were then compared with blue cells (non-fusogenic) as an accurate measure of fusion in different conditions. Crystallization and inhibitor soaking. For crystallization, the GP was treated with endo-β-acetylglucosaminidase F1 at 37 °C for 1 h, further purified with size-exclusion chromatography and concentrated to 10-12 mg ml −1 . Crystallization screen experiments were carried out using the nanolitre sitting-drop vapour diffusion method in 96-well plates as previously described 35 . Crystals were initially obtained from Hampton Research PEGRx 1 screen, condition 37 containing 10% (w/v) PEG 6,000 and 0.1 M sodium citrate tribasic dihydrate (pH 5.0). The best crystals were grown in the optimized condition containing 9% (w/v) PEG 6,000 and 0.1 M sodium citrate tribasic dihydrate at pH 5.2.
To obtain GP-inhibitor complexes, crystal-soaking experiments were performed. Crystal-soaking solutions were prepared by first dissolving the inhibitors in 100% DMSO and then diluting with 15% (w/v) PEG 6,000 and 0.1 M sodium citrate tribasic dihydrate (pH 5.0) to a final DMSO concentration of 10%. The inhibitor concentration was typically from 1 to 10 mM depending on solubility. Crystals were soaked in the above solutions for between 20 min and 5 h. Crystals soaked for longer normally diffracted less well and the crystals from which the GP-toremifene and GP-ibuprofen complex structures were obtained were only soaked for 20 min. Data collection and structure determination. Crystals were cryo-protected using solutions containing 75% crystallization liquor (or inhibitor soaking solution) and 25% (v/v) glycerol and frozen in liquid nitrogen before data collection. All data were collected from frozen crystals at 100 K. Data were acquired as 0.1° images on PILATUS 6M detectors at Diamond Light Source, using beamline I03 for native data (exposure time 0.1 s per frame, beam size 80 × 20 μm and 30% beam transmission), and I02 for inhibitor soaked crystals (exposure time 0.05 s per frame, beam size 90 × 25 μm and 40% beam transmission). Diffraction images were indexed, integrated and scaled with the automated data processing program Xia2-3dii 36 . The native data set was collected from four crystals to 2.23 Å resolution with 58-fold redundancy. A total of 7 inhibitors were soaked, including toremifene, tamoxifen, 4-hydroxyltamoxifen, raloxifene, clomiphene, ibuprofen and benztropine, and diffraction data were collected with resolutions ranging from 3.5 to 2.3 Å.
The crystals belong to space group R32 with unit cell dimensions a = b = 114.0 Å and c = 307.0 Å approximately. The apo structure was determined by molecular replacement with MOLREP 37 using the GP structure of the GP-KZ52 Fab complex (PDB ID, 3CSY) as a search model. There is one GP molecule in the crystal asymmetric unit. The biological trimer is formed by a crystallographic threefold axis. Structure refinement used REFMAC 38 and models were rebuilt with COOT 39 . The apo structure was refined to 2.23 Å resolution with an R work value of 0.223 (R free = 0.251) and good stereochemistry. Close examination of the data from inhibitor-soaked crystals showed that only toremifene and ibuprofen were fully bound with GP, and structures were refined to resolutions of 2.69 Å and 2.68 Å, respectively. 4-hydroxyltamoxifen was only bound with partial occupancy (data not shown). Data collection and structure refinement statistics are given in Extended Data Table 1 . Structural comparisons used SHP 40 
